This is the authors' abstract. We don't add key points for this paper.
Using CO 2 as a feedstock to produce high-value chemicals is attractive but remains far from effective in terms of technical application. In particular, efficient conversion of CO 2 into industrially important C 3+ diols is still challenging. Here, we present a carbon-negative electrochemical-biosynthesis cascade system for synthesizing C 3 –C 4 diols (1,3-propanediol, 1,3-PDO, and 1,3-butanediol, 1,3-BDO) directly from CO 2 at exceptionally high productivities. This integrated platform combines a CuZn-catalyzed electrochemical CO 2 reduction reactor operating at Ampere-level current densities (−1,100 mA cm –2 ) to produce ethanol (close to 1,200 μmol h –1 cm –2 ) with a biocatalytic module for C–C bond extension. A custom-designed J-T membrane prevents ethanol crossover, enabling accumulation to 4.6 g L –1 h –1, while engineered Thermotoga maritima DERA variants (S233D/F43T) exhibit enhanced catalytic efficiency through a synergistic approach combining AI and rational design, achieving a 1,3-PDO production rate of 1.8 g L –1 h –1 . In situ spectroscopic studies reveal that the presence of key intermediates *CO and *OH, along with the formation of a hydrogen-bonding network, significantly enhances the electrochemical synthesis of ethanol, while molecular dynamics simulations clarify mutation-induced conformational changes in DERA that improve substrate affinity. The system’s versatility is further demonstrated by extending ethanol to 1,3-BDO at 1.0 g L –1 h –1 . This work establishes a scalable paradigm for synthesizing multi-carbon diols from CO 2, bridging the gap between electrocatalysis and synthetic biology for sustainable manufacturing.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: